Company sponsors Spine Summit 2019 – 35th Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves
SAN DIEGO – March 6, 2019 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its participation in and sponsorship of Spine Summit 2019 – 35th Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves, held March 14–17, 2019 at the Fountainebleau Miami Beach. NuVasive will facilitate surgeon education experiences at the summit through participation in a surgery lab featuring the latest advances in lateral single-position surgery (LSPS) and hosting a workshop focused on Anterior Lumbar Interbody Fusion (ALIF) and Transforaminal Lumbar Interbody Fusion (TLIF) procedural solutions.
NuVasive will showcase its latest innovative spine solutions at booth #211 including:
- LSPS powered by Surgical Intelligence™ – connecting technology and tools to achieve optimized patient outcomes.
- Pulse™ surgical automation platform – the soon-to-be-launched technology will be on display, providing an opportunity to learn how this first-of-its-kind platform enables procedural integration of neuromonitoring, surgical planning, rod bending, smart imaging, navigation and automation.
Dr. Juan Uribe, chief of spinal disorders, Sonntag chair of spine research, and vice chairman of neurosurgery at Barrow Neurological Institute, will lead the LSPS surgery lab on Thursday, March 14. For more information on this hands-on education experience, visit the Congress of Neurological Surgeons event page.
“We encourage attendees to participate in the surgery lab to learn firsthand how incorporating lateral single-position surgery into their practice can help achieve better and more predictable patient outcomes,” said Matt Link, president of NuVasive. “NuVasive pioneered the lateral approach in spine surgery and we continue to lead the way in enabling surgeons to treat patients without repositioning during surgery, which may result in less time a patient is under anesthesia, less blood loss and fewer potential complications overall.”
Additionally, NuVasive will host a workshop titled: Leading, Expanding, Advancing Anterior Column Realignment: Insights to Lateral Procedural Solutions, ALIF and TLIF with presentations by Dr. Christopher Shaffrey, chief of spine surgery at Duke University School of Medicine, Dr. Adam Kanter, neurosurgeon at University of Pittsburgh Medical Center and Dr. Juan Uribe, on Thursday, March 14 from 12 p.m. to 1 p.m. in the Splash Ballroom.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor & Media Contact: